Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead and GSK nab early ADCs
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Tango missteps in PRMT5
The company abandons TNG908, but is still all in on the troubled target.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
